Albinterferon Alfa-2B

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Albinterferon Alfa-2B
Accession Number
DB05396
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Interferons
Description

Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

Protein chemical formula
C3796H5937N1015O1143S50
Protein average weight
85700.0 Da
Sequences
Not Available
Synonyms
  • alb-IFN
  • Albinterferon
  • Albuferon alpha
  • Albumin-interferon alpha
International/Other Brands
Albuferon
Categories
UNII
4DVS4AG4DF
CAS number
472960-22-8

Pharmacology

Indication

Investigated for use/treatment in hepatitis (viral, C).

Pharmacodynamics
Not Available
Mechanism of action

Interferons belong to a family of proteins known as cytokines that occur naturally in the human body. Cytokines control cellular processes, such as cell growth, activation, migration and aging. While the precise mechanism of action for interferon alpha is not known, research has demonstrated direct antiviral activity in patients with diseases like hepatitis C, as well as immune-modulating and direct antitumor effects in certain types of cancer.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Albinterferon Alfa-2B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Albinterferon Alfa-2B.
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Albinterferon Alfa-2B.
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Albinterferon Alfa-2B.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Albinterferon Alfa-2B.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Albinterferon Alfa-2B.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Albinterferon Alfa-2B.
9-MethylguanineThe metabolism of 9-Methylguanine can be decreased when combined with Albinterferon Alfa-2B.
AcefyllineThe metabolism of Acefylline can be decreased when combined with Albinterferon Alfa-2B.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Albinterferon Alfa-2B.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C: Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002 Nov;303(2):540-8. [PubMed:12388634]
External Links
PubChem Substance
347910117
Wikipedia
Albinterferon
ATC Codes
L03AB12 — Albinterferon alfa-2b

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections1
1, 2TerminatedTreatmentHepatitis B Chronic Infection1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection2
2CompletedTreatmentHepatitis C Viral Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:24 / Updated on June 04, 2019 06:16